Emma Walmsley, GlaxoSmithKline’s Chief Executive since last April,  announced plans to allocate capital to priority areas including respiratory and HIV and infectious diseases, and two potential areas of oncology and immuno-inflammation.

As consequences of the new focus of GSK,  more than 30 pre-clinical and clinical programs will be stopped, partnered or divested, and the group is considering options for its Rare Diseases unit after a strategic review.
“Q2 was another quarter of progress for GSK,” Walmsley said. “Our priority for the second half of the year is to maintain this momentum and prepare for the successful execution of several important near-term launches in Respiratory, Vaccines and HIV.”

Source: Reuters